Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial

By sjmartinez • June 7, 2024

Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. J Clin Oncol. 2024 Jun 6:JCO2400720. doi: 10.1200/JCO.24.00720. Epub ahead of print. PMID: 38843488.

Tags: Hematology/Oncology, Publications

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28polymorphism in[...]

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]